Last reviewed · How we verify
Lotrimin Daily Sweat and Odor Control (STARCH)
At a glance
| Generic name | STARCH |
|---|---|
| Sponsor | Bayer HealthCare LLC. |
| Therapeutic area | Infectious Disease |
| Phase | FDA-approved |
Approved indications
- minor skin irritation
Common side effects
- Pruritus (itching)
- Hemodilution
Serious adverse events
- Anaphylactoid reaction
- Hypersensitivity reaction
Key clinical trials
- Impact of Sugammadex Versus Neostigmine on Early Postoperative Pulmonary Function (NA)
- Effect of L. Reuteri LM1063 on Sleep Health Improvement (NA)
- Prebiotics, Gut Microbiota, and Cardiometabolic Health (NA)
- Effects of Probiotics on Respiratory Tract Infections in Children: A Randomized, Placebo-Controlled Interventional Study (PHASE2)
- The Effect of NP-2006 on Sleep Quality and Health (NA)
- Efficacy of Gou-Teng-San (GTS) in Patients With Episodic Migraine: A Double-Blind Randomized Controlled Trial (PHASE3)
- IRELAnD: Investigating the Role of Early Low-dose Aspirin in Diabetes (PHASE3)
- Probiotic Treatment for Depression and Associated Mood Disorders in Parkinson's Disease (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Lotrimin Daily Sweat and Odor Control CI brief — competitive landscape report
- Lotrimin Daily Sweat and Odor Control updates RSS · CI watch RSS
- Bayer HealthCare LLC. portfolio CI